Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide

The recent pandemic of COVID 19, caused by SARS-CoV-2, has been confirmed on May 8th in more than 3.5 million cases worldwide, carrying a mortality of approximately 2 –7% [1]. The elderly and patients with comorbidities may develop a severe progression of COVID-19, even whether the rate risk in immunosuppressed is still unknown [2].

Source: Journal of the Neurological Sciences - July 2, 2020 Category: Neurology Authors: Bollo Luca, Guerra Tommaso, Bavaro Davide Fiore, Monno Laura, Saracino Annalisa, Angarano Gioacchino, Paolicelli Damiano, Trojano Maria, Iaffaldano Pietro Tags: Letter to the Editor Source Type: research